Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
A clinical-stage gene therapy company focused on ocular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Gene therapy shot aims to tame wet AMD in both eyes
Disease control Recruiting nowThis study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…
Phase: PHASE2 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
One-Shot gene therapy could replace frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC